Low
₹165.10
High
₹196.44
| Previous Close | ₹183.73 |
|---|---|
| Day's Range | ₹165.10 - ₹196.44 |
| Open | ₹166.70 |
| 52 Week Range | ₹132.30 - ₹226.00 |
| Volume | 5,12,82,284 |
| Market Cap | ₹0.02 |
| Previous Close | ₹183.85 |
|---|---|
| Day's Range | ₹165.10 - ₹196.40 |
| Open | ₹168.00 |
| 52 Week Range | ₹132.50 - ₹226.00 |
| Volume | 16,29,473 |
| Market Cap | ₹0.02 |
| Trade Value ( ₹ in Lacs) | 94,220.94 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -2.45 |
| P/E Ratio | 326.26 |
| Book Value(₹) | 2.69 |
| PAT Margin (%) | 0.86 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.61 |
| Trade Value ( ₹ in Lacs) | 2,995.79 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -2.45 |
| P/E Ratio | 326.26 |
| Book Value(₹) | 2.69 |
| PAT Margin (%) | 0.86 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.61 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 52857.1 | 27540.7 |
| Expenses | N/A | N/A |
| PBT | 9111.4 | 2728.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 6914.0 | 1535.0 |
| Founded | 2020 |
|---|---|
| NSE Symbol | PPLPHARMA |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,831.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,681.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,351.60 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,460.50 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,820.45 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,361.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,307.00 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,015.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,375.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 940.10 | 835.50 - 835.50 |
No Records Found
Piramal Pharma has informed that as per the information received by the Company on March 20, 2026, SES ESG Research (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘68.5’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year. The link for the rating as published is also available on the website. The Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company. This intimation is also being uploaded on the website of the Company at https://www.piramalpharma.com/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Piramal Pharma Ltd. is ₹183.73 as of 2026-05-07.
The market capitalisation of Piramal Pharma Ltd. is ₹21,945.89 as of 2026-05-06.
The 1-year return of Piramal Pharma Ltd. is 0.00% as of 2026-05-07.
The P/E ratio of Piramal Pharma Ltd. is 326.26 as of 2026-05-07.
The 52-week high and low of Piramal Pharma Ltd. are ₹226.00 and ₹132.30, respectively, as of 2026-05-07.
Piramal Pharma Ltd. manufactures a range of complex hospital generics, including inhalation anesthetics and injectables. The company also offers a line of consumer healthcare products and provides comprehensive contract development and manufacturing services (CDMO) for global firms.
Piramal Pharma Ltd. establishes partnerships by offering extensive CDMO services, acting as an integrated manufacturing partner for global pharmaceutical innovators. The firm also partners directly with major healthcare institutions to supply hospital generics and complex anesthesia products.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.